Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease
about
Positioning new pharmacotherapies for COPDPhosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.The standardized herbal formula, PM014, ameliorated cigarette smoke-induced lung inflammation in a murine model of chronic obstructive pulmonary disease.Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease.Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice.Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors
P2860
Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Roflumilast (daliresp): a nove ...... obstructive pulmonary disease
@ast
Roflumilast (daliresp): a nove ...... obstructive pulmonary disease
@en
type
label
Roflumilast (daliresp): a nove ...... obstructive pulmonary disease
@ast
Roflumilast (daliresp): a nove ...... obstructive pulmonary disease
@en
prefLabel
Roflumilast (daliresp): a nove ...... obstructive pulmonary disease
@ast
Roflumilast (daliresp): a nove ...... obstructive pulmonary disease
@en
P2860
P1476
Roflumilast (daliresp): a nove ...... obstructive pulmonary disease
@en
P2093
Jordan Baye
P2860
P304
P577
2012-03-01T00:00:00Z